Targeting Solid Cancers With CAR-T: Japan’s Noile-Immune Looks To Partner Platform

 
• By Lisa Takagi

Setting a strategic focus on solid cancers with its enhanced PRIME CAR-T technology, Koji Tamada, CEO of Noile-Immune, shared the Japanese bioventure's collaboration strategies and views on the next generation of cell therapies. 

Noile's CAR-T therapy candidates target solid tumor.
Noile-Immune's CAR-T candidates target solid tumors • Source: Shutterstock

More from Japan

More from Focus On Asia